Id: | acc0676 |
Group: | 1sens |
Protein: | RUNX1 |
Gene Symbol: | RUNX1 |
Protein Id: | Q01196 |
Protein Name: | RUNX1_HUMAN |
PTM: | phosphorylation |
Site: | Ser94 |
Site Sequence: | LPIAFKVVALGDVPDGTLVTV |
Disease Category: | Cancer |
Disease: | Leukemia |
Disease Subtype: | CML |
Disease Cellline: | |
Disease Info: | |
Drug: | imatinib |
Drug Info: | "Imatinib is a tyrosine kinase inhibitor that targets Bcr-Abl and KIT proteins, used in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST)." |
Effect: | inhibit |
Effect Info: | Metformin can inhibit STAT3 phosphorylation through AMPK - induced RUNX1 (Ser94) phosphorylation and enhance imatinib sensitivity in imatinib - resistant subjects. |
Note: | |
Score: | 5.0 |
Pubmed(PMID): | 37903788 |
Sentence Index: | 37903788_0 |
Sentence: | AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects. |
Sequence & Structure:
MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
RUNX1-Ser17 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | 0.196 | ||||
HGSC | 1.773 | ||||
ccRCC | -0.488 | ||||
GBM | -0.998 | ||||
HNSC | -0.027 | ||||
LUAD | -1.089 | ||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC | 0.632 |
RUNX1-Ser193 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | 0.707 | ||||
COAD | |||||
HGSC | -0.707 | ||||
ccRCC | |||||
GBM | |||||
HNSC | |||||
LUAD | |||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC |
RUNX1-Ser21 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | -2.457 | ||||
COAD | 0.432 | ||||
HGSC | 0.165 | ||||
ccRCC | 0.607 | ||||
GBM | 0.05 | ||||
HNSC | 0.7 | ||||
LUAD | -0.021 | ||||
LUSC | 0.389 | ||||
non_ccRCC | -1.291 | ||||
PDAC | 0.878 | ||||
UCEC | 0.548 |
RUNX1-Ser212 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | -1.606 | ||||
COAD | -1.106 | ||||
HGSC | 0.909 | ||||
ccRCC | 0.257 | ||||
GBM | 0.212 | ||||
HNSC | 1.488 | ||||
LUAD | -0.2 | ||||
LUSC | 0.596 | ||||
non_ccRCC | -1.3 | ||||
PDAC | 0.958 | ||||
UCEC | -0.209 |
RUNX1-Ser249 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | |||||
HGSC | -1.611 | ||||
ccRCC | |||||
GBM | 0.72 | ||||
HNSC | 0.549 | ||||
LUAD | -0.342 | ||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC | 0.683 |
RUNX1-Ser257 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | |||||
HGSC | |||||
ccRCC | |||||
GBM | |||||
HNSC | 0.707 | ||||
LUAD | -0.707 | ||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC |
RUNX1-Ser263 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | |||||
HGSC | |||||
ccRCC | |||||
GBM | |||||
HNSC | -0.243 | ||||
LUAD | -0.856 | ||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC | 1.099 |
RUNX1-Ser268 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | |||||
HGSC | -1.271 | ||||
ccRCC | |||||
GBM | 0.193 | ||||
HNSC | -0.08 | ||||
LUAD | |||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC | 1.158 |
RUNX1-Ser50 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | |||||
HGSC | |||||
ccRCC | |||||
GBM | |||||
HNSC | |||||
LUAD | 0.707 | ||||
LUSC | |||||
non_ccRCC | |||||
PDAC | -0.707 | ||||
UCEC |
RUNX1-Thr14 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | 0.412 | ||||
COAD | -0.055 | ||||
HGSC | 1.822 | ||||
ccRCC | 0.026 | ||||
GBM | 0.071 | ||||
HNSC | 0.179 | ||||
LUAD | -0.889 | ||||
LUSC | 0.053 | ||||
non_ccRCC | -2.327 | ||||
PDAC | 0.279 | ||||
UCEC | 0.43 |
RUNX1-Thr18 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | |||||
HGSC | |||||
ccRCC | -0.305 | ||||
GBM | 1.025 | ||||
HNSC | -0.242 | ||||
LUAD | -1.398 | ||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC | 0.919 |
RUNX1-Tyr258 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | |||||
HGSC | |||||
ccRCC | |||||
GBM | |||||
HNSC | 0.707 | ||||
LUAD | -0.707 | ||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC |
RUNX1-Tyr260 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | |||||
HGSC | |||||
ccRCC | |||||
GBM | |||||
HNSC | -0.552 | ||||
LUAD | -0.602 | ||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC | 1.154 |
RUNX1T1-Ser14 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | -0.707 | ||||
COAD | |||||
HGSC | |||||
ccRCC | |||||
GBM | |||||
HNSC | |||||
LUAD | |||||
LUSC | 0.707 | ||||
non_ccRCC | |||||
PDAC | |||||
UCEC |
RUNX1T1-Ser390 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | 0.407 | ||||
COAD | -0.559 | ||||
HGSC | 1.361 | ||||
ccRCC | -1.198 | ||||
GBM | |||||
HNSC | 1.786 | ||||
LUAD | -0.58 | ||||
LUSC | -0.139 | ||||
non_ccRCC | -0.957 | ||||
PDAC | 0.558 | ||||
UCEC | -0.679 |
RUNX1T1-Thr25 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | |||||
HGSC | -0.965 | ||||
ccRCC | |||||
GBM | |||||
HNSC | -0.066 | ||||
LUAD | |||||
LUSC | |||||
non_ccRCC | |||||
PDAC | 1.032 | ||||
UCEC |
RUNX1T1-Thr565 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | 1.488 | ||||
HGSC | |||||
ccRCC | |||||
GBM | |||||
HNSC | -0.938 | ||||
LUAD | |||||
LUSC | -0.915 | ||||
non_ccRCC | |||||
PDAC | 0.19 | ||||
UCEC | 0.175 |
RUNX1T1-Thr568 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | 1.663 |
HGSC | |
ccRCC | |
GBM | |
HNSC | -1.05 |
LUAD | |
LUSC | -0.138 |
non_ccRCC | |
PDAC | -0.232 |
UCEC | -0.244 |
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
R | 233 | C | Acute myelogenous leukemia | Methylation | 32573733 |
R | 237 | C | Acute myelogenous leukemia | Methylation | 32573733 |
R | 223 | P | Myeloid | Methylation | 24332853 |
T | 207 | U | Breast cancer | Phosphorylation | 32549768 |
- | - | U | Glioblastoma | Ubiquitination | 36949071 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.